

RECENT THERAPIES FOR HR+/HER2- BREAST CANCER

with **Kevin Kalinsky**
Winship Cancer Institute
of Emory University (GA, USA)

Operable breast cancer



- Endocrine therapy remains the standard of care for systemic therapy



- Chemotherapy for some patients - depending on risk



- Recent approval for Verzenios® (abemaciclib), based on the Monarch-E trial



Limitations and challenges of current treatments

Identifying whether premenopausal women can replace chemotherapy with ovarian function suppression

How can the 21-Gene Assay inform treatment sequencing?

- In RxPONDER, postmenopausal women with recurrence score 0–25 do not benefit from chemotherapy if 1–3 lymph nodes involved
- Premenopausal women with these characteristics, however, benefit from chemotherapy



Future predictions for HER-2 breast cancer treatment options

- An increasing role for circulating markers - such as ctDNA
- As well as exciting endocrine agents, such as oral selective estrogen receptor down regulators

Interviewee profile

Name:

Kevin Kalinsky

Affiliation:

Director of the Glenn Family Breast Center and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University (GA, USA)



EMORY
WINSHIP
CANCER
INSTITUTE
National Cancer Institute Designated
Comprehensive Cancer Center